Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and ...

The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders. New disclosures show Trump bought bonds affected by government policy changes ...

Septerna's Novo partnership brings $195M upfront, a potential $2.2B in milestones, and full R&D funding. Read why SEPN stock ...

Discover Boehringer Ingelheim’s pipeline focus areas and how its dealmaking in 2025 has expanded its therapeutic arsenal.

On November 10, 2025, BMO Capital reiterated its “Outperform” rating on Structure Therapeutics Inc. (NASDAQ:GPCR), setting a ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

Chemerin is a key adipokine that regulates lipid metabolism and insulin sensitivity, and thus is involved in many metabolic ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a ...

As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new ...

Pharmaceuticals announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic ...

The Tectonic management team will host one-on-one meetings during the two conferences. Interested investors should contact their Piper Sandler and Evercore representatives to schedule meetings.